
All statements of endorsement from the American Academy of Pediatrics automatically expire 5 years after publication unless reaffirmed, revised, or retired at or before that time.
Statement of Endorsement: Corticosteroid Treatment of Duchenne Muscular Dystrophy

Pediatrics; originally published online May 23, 2016;
DOI: 10.1542/peds.2016-0853

Updated Information & Services
including high resolution figures, can be found at:
/content/early/2016/05/19/peds.2016-0853.full.html

Subspecialty Collections
This article, along with others on similar topics, appears in the following collection(s):
Neurology
/cgi/collection/neurology_sub
Neurologic Disorders
/cgi/collection/neurologic_disorders_sub

Permissions & Licensing
Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at:
/site/misc/Permissions.xhtml

Reprints
Information about ordering reprints can be found online:
/site/misc/reprints.xhtml

PEDIATRICS is the official journal of the American Academy of Pediatrics. A monthly publication, it has been published continuously since 1948. PEDIATRICS is owned, published, and trademarked by the American Academy of Pediatrics, 141 Northwest Point Boulevard, Elk Grove Village, Illinois, 60007. Copyright © 2016 by the American Academy of Pediatrics. All rights reserved. Print ISSN: 0031-4005. Online ISSN: 1098-4275.
Statement of Endorsement: Corticosteroid Treatment of Duchenne Muscular Dystrophy

*Pediatrics*; originally published online May 23, 2016;
DOI: 10.1542/peds.2016-0853

The online version of this article, along with updated information and services, is located on the World Wide Web at:
/content/early/2016/05/19/peds.2016-0853.full.html